Bluejay Diagnostics (NASDAQ:BJDX) Stock Price Down 3.7% – Time to Sell?

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was down 3.7% during trading on Tuesday. The company traded as low as $0.6651 and last traded at $0.6705. 48,210 shares changed hands during trading, a decline of 94% from the average session volume of 770,895 shares. The stock had previously closed at $0.6964.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BJDX. Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Monday, September 21st. Wall Street Zen lowered shares of Bluejay Diagnostics from a “hold” rating to a “sell” rating in a report on Monday, September 14th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Bluejay Diagnostics Stock Performance

The firm has a market cap of $2.81 million, a PE ratio of -0.09 and a beta of 0.89. The company’s 50-day simple moving average is $0.88 and its two-hundred day simple moving average is $1.70.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc is a medical technology company focused on developing rapid, decentralized diagnostic solutions for use at the point of care. The company’s products are designed to help healthcare professionals obtain timely information from blood samples, supporting clinical decision-making in acute-care settings.

Bluejay’s primary technology is the Symphony System, a compact analyzer and disposable testing platform intended to measure clinically relevant biomarkers from whole blood.